Health Care • Misc Health and Biotechnology Services
$28.40 ▲ +0.53
(+1.90%)
MKT CAP: $2.18B • VOL: 657.5K
52W L $16 52W H $33
PGNY // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.29B | $1.17B | $1.09B |
| YoY Revenue Growth % | +10.4% | +7.2% | — |
| Gross Profit | $304.5M | $253.4M | — |
| Gross Margin % | 23.6% | 21.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $85.3M | $67.5M | $62.2M |
| Operating Margin % | 6.6% | 5.8% | 5.7% |
| Net Income (GAAP) | $58.5M | $54.3M | $62.0M |
| EBITDA (Normalized) | $100.0M | $71.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $210.2M | $179.1M | $188.8M |
| Capital Expenditures (CapEx) | $18.4M | $5.4M | — |
| Free Cash Flow (FCF) | $191.8M | $173.7M | $188.8M |
| FCF Margin % | 14.9% | 14.9% | 17.3% |
| Return on Invested Capital (ROIC %) | 16.7% | 20.5% | — |
| Cash & Short-Term Equivalents | $112.2M | $162.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $516.0M | $422.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PGNY.